NO20051108L - Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse - Google Patents

Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse

Info

Publication number
NO20051108L
NO20051108L NO20051108A NO20051108A NO20051108L NO 20051108 L NO20051108 L NO 20051108L NO 20051108 A NO20051108 A NO 20051108A NO 20051108 A NO20051108 A NO 20051108A NO 20051108 L NO20051108 L NO 20051108L
Authority
NO
Norway
Prior art keywords
taxanes
binding agent
therapeutic use
cytotoxic agents
agents containing
Prior art date
Application number
NO20051108A
Other languages
English (en)
Inventor
Erkan Balogiu
Michael Miller
Ravi V J Chari
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/369,563 external-priority patent/US7390898B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20051108L publication Critical patent/NO20051108L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Epoxy Compounds (AREA)

Abstract

Omfattet innenfor foreliggende oppfinnelses område er kraftig virkende taxaner som inneholder en tilkoblingsgruppe. Videre omfattes et cytotoksisk middel som omfatter et eller flere taxaner koblet til et cellebindende middel. Et terapeutisk preparat for induksjon av celledød i utvalgte cellepopulasjoner som omfatter: (A) en cytotoksisk mengde av et eller flere taxaner kovalent bundet til et cellebindende middel via en tilkoblingsgruppe, og (B) et farmasøytisk aksepterbart bærestoff, fortynningsmiddel eller en eksipiens omfattes også. En fremgangsmåte for induksjon av celledød i utvalgte cellepopulasjoner som omfatter å sette målceller eller vev som inneholder målceller i forbindelse med en effektiv mengde av et cytotoksisk middel som omfatter et eller flere taxaner koblet fil et cellebindende middel omfattes også.
NO20051108A 2002-08-02 2005-03-01 Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse NO20051108L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21011202A 2002-08-02 2002-08-02
US10/369,563 US7390898B2 (en) 2002-08-02 2003-02-21 Cytotoxic agents containing novel potent taxanes and their therapeutic use
PCT/US2003/019558 WO2004013093A2 (en) 2002-08-02 2003-07-14 Cytotoxic agents containing novel potent taxanes and their therapeutic use

Publications (1)

Publication Number Publication Date
NO20051108L true NO20051108L (no) 2005-05-02

Family

ID=31498026

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051108A NO20051108L (no) 2002-08-02 2005-03-01 Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse

Country Status (12)

Country Link
US (2) US7495114B2 (no)
EP (1) EP1534674A4 (no)
JP (1) JP2005539009A (no)
KR (1) KR20050032110A (no)
CN (1) CN100522955C (no)
AU (1) AU2003247587B2 (no)
BR (1) BR0313197A (no)
CA (1) CA2494074A1 (no)
IL (1) IL166624A0 (no)
MX (1) MXPA05001390A (no)
NO (1) NO20051108L (no)
WO (1) WO2004013093A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446317T1 (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
CA2569132A1 (en) * 2004-06-03 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
EP1688415A1 (en) * 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
EP1888121A2 (en) * 2005-05-12 2008-02-20 Tapestry Pharmaceuticals, Inc. Anticancer targeted conjugates comprising a succinyl or glutaryl linker
AU2007274738B2 (en) 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
CA2700378A1 (en) * 2007-09-21 2009-03-29 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2742388C (en) * 2007-11-08 2019-02-19 Virginia Tech Intellectual Properties, Inc. Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents
KR101984053B1 (ko) 2009-02-05 2019-05-30 이뮤노젠 아이엔씨 신규한 벤조디아제핀 유도체
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
WO2012112708A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
BR112013032928A2 (pt) 2011-06-21 2017-01-24 Immunogen Inc "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015096553A1 (zh) * 2013-12-24 2015-07-02 于跃 抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
TWI697493B (zh) 2014-09-03 2020-07-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
SG11201704487XA (en) 2014-12-04 2017-06-29 Celgene Corp Biomolecule conjugates
EP3313845B1 (en) 2015-06-29 2020-08-12 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
CN113087763A (zh) 2015-07-21 2021-07-09 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
EP3380525B1 (en) 2015-11-25 2023-11-08 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP7203729B2 (ja) 2016-11-23 2023-01-13 イミュノジェン・インコーポレーテッド ベンゾジアゼピン誘導体の選択的スルホン化
IL298414A (en) 2017-02-28 2023-01-01 Immunogen Inc History of methanosinoids with peptide linkers and their conjugates
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
JP2022529583A (ja) 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス－ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体
ES2966473T3 (es) 2019-04-26 2024-04-22 Immunogen Inc Derivados de camptotecina
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US20210283125A1 (en) 2020-02-25 2021-09-16 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
WO2024023735A1 (en) 2022-07-27 2024-02-01 Mediboston Limited Auristatin derivatives and conjugates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6028205A (en) * 1991-09-23 2000-02-22 Florida State University C2 tricyclic taxanes
US5728725A (en) * 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
US5399726A (en) * 1993-01-29 1995-03-21 Florida State University Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US6339164B1 (en) * 1993-01-29 2002-01-15 Florida State University C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) * 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
AU4001295A (en) * 1994-10-14 1996-05-06 Hauser Chemical Research, Inc. New cytotoxic agents
AU4548296A (en) * 1995-02-02 1996-08-21 Daiichi Pharmaceutical Co., Ltd. Ether derivative
CN1211919A (zh) * 1995-09-13 1999-03-24 佛罗里达州立大学 放射增敏性紫杉烷及其药物制剂
JP4172726B2 (ja) 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
AU5159798A (en) 1996-11-05 1998-05-29 Bristol-Myers Squibb Company Branched peptide linkers
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
BR9809138A (pt) 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
WO1999018113A1 (fr) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2000050059A1 (en) * 1999-02-24 2000-08-31 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
AU765588C (en) * 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6175023B1 (en) * 2000-01-31 2001-01-16 Jian Liu Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III
ATE413397T1 (de) * 2000-02-02 2008-11-15 Univ Florida State Res Found Heterosubstituierte c7-taxanacetate als antitumormittel
AU776767B2 (en) * 2000-02-02 2004-09-23 Florida State University Research Foundation, Inc. C10 heterosubstituted acetate taxanes as antitumor agents
AU776122B2 (en) * 2000-02-02 2004-08-26 Florida State University Research Foundation, Inc. C7 carbonate substituted taxanes as antitumor agents
IL145635A0 (en) * 2000-02-02 2002-06-30 Univ Florida State Res Found Taxane formulations having improved solubility
ATE392422T1 (de) * 2000-02-02 2008-05-15 Univ Florida State Res Found C7-carbamoyloxysubstituierte taxane als antitumormittel
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Also Published As

Publication number Publication date
CA2494074A1 (en) 2004-02-12
MXPA05001390A (es) 2005-07-29
EP1534674A2 (en) 2005-06-01
KR20050032110A (ko) 2005-04-06
WO2004013093A3 (en) 2004-07-01
US20050026997A1 (en) 2005-02-03
US20050085513A1 (en) 2005-04-21
CN100522955C (zh) 2009-08-05
IL166624A0 (en) 2006-01-15
CN1684948A (zh) 2005-10-19
US7414073B2 (en) 2008-08-19
US7495114B2 (en) 2009-02-24
BR0313197A (pt) 2005-08-09
EP1534674A4 (en) 2007-11-28
AU2003247587A1 (en) 2004-02-23
AU2003247587B2 (en) 2009-07-09
JP2005539009A (ja) 2005-12-22
WO2004013093A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
NO20051108L (no) Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse
DK1242401T3 (da) Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
DK1242438T3 (da) Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
KR100850331B1 (ko) 이온화 방사선 독성으로부터 세포 및 조직을 보호하는데 사용되는 약학적 조성물
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
UY29875A1 (es) Compuestos quimicos
DK0923570T3 (da) Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler
UA86957C2 (ru) Производные азепиноиндола в качестве фармацевтического средства
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
UY30736A1 (es) Compuestos quimicos 537
NO952132L (no) Farmakologiske aktive pyridin-derivater og deres fremstilling
SE9904505D0 (sv) Novel compounds
NO20072915L (no) Farmasoytisk preparat som inneholder belagte magnetiske partikler og fremgangsmate for fremstilling av disse, og diagnoseterapisystem
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
AU3850600A (en) Dalda analogs and their use
AU2003255355A1 (en) Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
AUPR118000A0 (en) Therapeutic molecules and methods
NO20060561L (no) Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater
SE0102057D0 (sv) New Salts I
NO20056005L (no) Terapautiske midler
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm